This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Finegold, S. M.
Right arrow Articles by Väisänen, M.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finegold, S. M.
Right arrow Articles by Väisänen, M.-L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2009, p. 281-286, Vol. 53, No. 1
0066-4804/09/$08.00+0     doi:10.1128/AAC.00441-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Study of the In Vitro Activities of Rifaximin and Comparator Agents against 536 Anaerobic Intestinal Bacteria from the Perspective of Potential Utility in Pathology Involving Bowel Flora{triangledown}

S. M. Finegold,1,2,3,4* D. Molitoris,2 and M.-L. Väisänen2

Medical,1 Research Services, VA Greater Los Angeles Healthcare System,2 Departments of Medicine,3 Microbiology, Immunology, and Molecular Genetics, UCLA School of Medicine, Los Angeles, California4

Received 3 April 2008/ Returned for modification 5 May 2008/ Accepted 17 October 2008

Rifaximin, ampicillin-sulbactam, neomycin, nitazoxanide, teicoplanin, and vancomycin were tested against 536 strains of anaerobic bacteria. The overall MIC of rifaximin at which 50% of strains were inhibited was 0.25 µg/ml. Ninety percent of the strains tested were inhibited by 256 µg/ml of rifaximin or less, an activity equivalent to those of teicoplanin and vancomycin but less than those of nitazoxanide and ampicillin-sulbactam.

* Corresponding author. Mailing address: Greater Los Angeles VAMC, 11301 Wilshire Blvd., Bldg. 304, Rm. E3-237, Los Angeles, CA 90073. Phone: (310) 268-3678. Fax: (310) 268-3594. E-mail: sidfinegol{at}aol.com

{triangledown} Published ahead of print on 27 October 2008.

Antimicrobial Agents and Chemotherapy, January 2009, p. 281-286, Vol. 53, No. 1
0066-4804/09/$08.00+0     doi:10.1128/AAC.00441-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»